Page 133 - Drug Class Review

Communicative Disorders and Stroke—Alzheimer Disease and Related Disorders Association with
one exception where a DSM-IV diagnosis of dementia was used for inclusion; Fourteen of 22 trials
Drug Effectiveness Review Project
Duration of treatment varied between six weeks and three years; Number of patients included per
probable or possible Alzheimer’s disease, according to the National Institute of Neurological and
study varied between 27 and 978; All studies included patients with an established diagnosis of

to assess efficacy used the ADAS-cog as the primary measurement of efficacy; In 12 trials, the CIBIC-plus was used Methodological assessment of all studies found considerable flaws: The use of several “primary end points without correction for multiple comparisons. After correction, two of the five trials on rivastigmine do not show any significant benefit on primary endpoint measures any more; missing ITT analysis, as in 15 of the 22 trials patients were excluded from analysis after randomization; In at least eight of the trials the last observation carried forwa

• Yes Yes Good

Final Report Update 1 Authors: Kaduszkiewicz et al. Year: 2005 CHARACTERISTICS OF INTERVENTIONS: MAIN RESULTS: ADVERSE EVENTS: COMPREHENSIVE LITERATURE SEARCH STRATEGY: STANDARD METHOD OF APPRAISAL OF STUDIES: QUALITY RATING: Alzheimer's Drugs